Company Filing History:
1 out of 5,094 
1 out of 23 Years Active: 2012
Title: Catherine Widmann: Innovator in Psychiatric Treatment
Introduction
Catherine Widmann is a notable inventor based in La Colle sur Loup, France. She has made significant contributions to the field of psychiatric treatment through her innovative research and development of new therapeutic agents.
Latest Patents
Catherine Widmann holds a patent for a peptide derived from neurotensin receptor 3 (NTSR3) and its use in the treatment of psychiatric diseases. This invention is particularly focused on the development of a drug, such as an antidepressant, that utilizes this peptide. The peptide is characterized by the sequence identified as SEQ ID No. 2. The implications of this invention extend to the pharmaceutical industry, especially in drug development aimed at treating psychiatric conditions. Additionally, it has potential applications in the treatment of pain and inflammation.
Career Highlights
Throughout her career, Catherine has worked with esteemed institutions, including the Centre National de la Recherche Scientifique and the Université de Nice-Sophia Antipolis. Her work has been instrumental in advancing the understanding and treatment of psychiatric diseases.
Collaborations
Catherine has collaborated with notable colleagues such as Jean Mazella and Olivier Petrault, contributing to her innovative research and development efforts.
Conclusion
Catherine Widmann's contributions to the field of psychiatric treatment through her patented peptide represent a significant advancement in drug development. Her work continues to inspire future innovations in the pharmaceutical industry.